Tokyo, Japan – March 4th 2025 – Pei Hao, Founder and CEO of MobiDrop, a leading innovator in single-cell analysis technologies, recently visited Tokyo, Japan, to strengthen strategic partnerships with key distributors and research collaborators. During the visit, Mr. Hao held high-level discussions with Toyo Corporation (8151:TYO), a prestigious Japanese listed company with a long-standing reputation in scientific instrumentation distribution, and explored collaborative opportunities with DNA Institute and Fuji Film, two prominent players in Japan’s life sciences sector.

Strengthening Ties with Toyo Corporation

Toyo Corporation, a Tokyo Stock Exchange-listed company with decades of experience in the distribution of advanced scientific and medical equipment, serves as MobiDrop’s distributor in Japan. The meeting focused on expanding market penetration for MobiDrop’s cutting-edge single-cell  sequencing solutions, leveraging Toyo’s extensive commercial network across academia and industry.

"Toyo Corporation’s deep expertise and established presence in Japan make them an invaluable partner for MobiDrop’s growth in this key market," said Pei Hao. "We are confident that our collaboration will accelerate the adoption of single-cell technologies among Japanese researchers and biotech firms."

Exploring Innovation with DNA Institute and Fuji Film

In addition to the discussions with Toyo, Mr. Hao visited DNA Institute, a leading service provider specializing in single-cell genomics, and Fuji Film, a global leader in life sciences. These meetings yielded preliminary agreements on potential orders for MobiDrop’s single-cell platforms, with further technical evaluations underway.

"Japan is at the forefront of single-cell research, and partnerships with institutions like DNA Institute and Fuji Film will help us refine our technology for broader applications," Mr. Hao noted.

Next Steps: Accelerating Market Expansion

The visit underscored MobiDrop’s commitment to the Japanese market and set the stage for deeper collaborations in 2025. With growing demand for high-precision single-cell technologies in drug discovery, cancer research, and synthetic biology, MobiDrop aims to solidify its presence in Asia through strategic alliances.